
Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA).
In May 2025, the Division of Neurology 1 within the Office of Neuroscience of the Food and Drug Administration (FDA) informed the company that it was extending the Prescription Drug User Free Act (PDUFA) date for the troriluzole NDA by three months to provide time for a full review of the company’s recent data submissions.